Publication date: Jul 02, 2021
More than half of these people eventually transition to secondary progressive MS, which is a slow, steady, worsening of the disease that may or may not include relapses. People in the high-efficacy group experienced an average of 0. 17 relapses per year compared 0. 27 relapses per year in the low-efficacy group. But when the goal is to limit disability progression in secondary progressive MS, both types of drugs show comparable effectiveness. “A limitation of the study was that participants were grouped by those taking high-efficacy or low-efficacy therapies. “When the goal is to alleviate ongoing relapse activity, more potent therapy is justified.